Bullish & Foolish
Full CLNN fundamentals All 466 on the Survival Watch

CLNNClene Inc.

Is Clene struggling financially?

Yes, by its own account. Clene told the SEC on 14 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

27/100

Fragile

Sector
Biotech/Pharma
Market cap
$55.5M
Source filing
10-Q 14 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 5months

    If the burn speeds up

    Empty by Nov 2026

  • 8months

    If it eases off

    Empty by Mar 2027

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$9.7M

÷

Cash burned over the last 12 months

$18.6M

What Clene told the SEC

…cash and cash equivalents of at least $ 2.0 million to avoid acceleration of the full balance of the 2024 SSCP Notes (see Note 8 ). These conditions raise substantial doubt about the Company’s ability to continue as a going concern. To mitigate our funding needs, we plan to raise additional funding, including exploring equity financing and offerings, debt financing, licensing or collaboration arrangements with…

Clene Inc., Form 10-Q, filed 14 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 30.9% share-count increase The company issued stock. Each share now owns 23.6% less of the business than a year ago, before any change in the price.
  • Debt pressure is material Operating earnings cover only -7.2x the interest bill, so the interest is being met out of cash reserves rather than out of the business.
  • Cash burn is narrowing It is spending 49% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt